Dr Charles Mullighan speaks to ecancer at the 2019 ASH meeting about the use of transcriptome and genomic sequencing to understand the genetic basis of acute myeloid leukaemia (AML) and myelodysplastic syndromes.
He explains the background and methodology of this study and the sequencing techniques used.
Dr Mullighan states that new mutational targets were identified, along structural changes such as deletions and rearrangements. Particular mutations were associated with very poor outcomes.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.
Watch the press conference here.
Read more about the study here.